A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.

ABSTRACT: Vaccine development for vector-borne pathogens may be accelerated through the use of relevant challenge models, as has been the case for malaria. Because of the demonstrated biological importance of vector-derived molecules in establishing natural infections, incorporating natural challenge models into vaccine development strategies may increase the accuracy of predicting efficacy under field conditions. Until recently, however, there was no natural challenge model available for the evaluation of vaccine candidates against visceral leishmaniasis. We previously demonstrated that a candidate vaccine against visceral leishmaniasis containing the antigen LEISH-F3 could provide protection in preclinical models and induce potent T-cell responses in human volunteers. In the present study, we desc

SUBMITTER: Duthie MS 

PROVIDER: S-EPMC5627294 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature